Shots:

• The approval is based on P-III ARAMIS study assessing Nubeqa (600mg- qd) + ADT vs PBO + ADT in 1-509 patients in a ratio (2:1) with nmCRPC
• The P-III ARAMIS study results: improvement in 1EPs of MFS (40.4mos. vs 18.4mos.); MFS is supported by delay in time to pain progression and other 2EPs i.e- time to cytotoxic CT- time to SSE
• Nubeqa is an Ari- co-developed by Bayer and Orion Corporation- being evaluated in P-III ARASENS study for m-hormone-sensitive PC and an approved therapy in the US and Brazil and is underway in EU and other regions

Click here ­to­ read full press release/ article | Ref: Bayer | Image: BioSpace